Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese ADC, RNA Therapy Developers Lead May/June Fundraising

Executive Summary

Emerging companies including Bliss Biopharmaceutical, Coherent Biopharma and WestGene Biopharma lifted China biotech funding from May to mid-June.

You may also be interested in...



New Results Provide Glimpse Into BlissBio's Enhertu Challenger In HER2-Low Breast Cancer

China's BlissBio has unveiled new clinical results for its HER2-targeting ADC BB-1701 in HER2-low breast cancer, which showed “promising” preliminary efficacy and "manageable" safety, in a glimpse into the Enhertu challenger's potential. 

Eisai Boards Fast Boat To China In HER2-Targeting ADC Deal With Bliss

The Japanese drug maker is the second in the space of a month to partner up with a Chinese biotech firm for a HER2-targeting antibody-drug conjugate, as ADCs gain more interest from large pharma firms.

China Biotech Podcast: Shanghai Policy, US Draft Biosecure Bill, MNCs' China Strategy

Brian Yang, Dexter Yan and guest speaker Kevin Grogan from the UK discuss Shanghai's latest policy to spur biopharma investment, the US House's recent draft bill to restrict bio service providers from China, and multinationals' strategies in China and views on Chinese innovation.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148615

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel